Drug Trial Radar · NCT05667987
Evaluation of the Benefit of Lidocaine on the Prevention of the Risk of Post Endoscopic Retrograde Cholangio-pancreatography Pancreatitis.
Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,800
Planned (sponsor's estimate)
Start
Jan 18, 2024
Primary completion
Jan 18, 2026
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- GCS Ramsay Santé pour l'Enseignement et la RechercheAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 29, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is, in a population of patients undergoing ERCP surgery, treated preventively with NSAIDs and divided into two groups according to the absence (group 1) or presence (group 2) of intravenous lidocaine in the general anesthesia protocol. The main objective of this study is to compare the incidence of post-ERCP pancreatitis between the two groups. type of study: clinical trial participant population/health conditions: Patients with ERCP surgery
Conditions
- ERCP Surgery
Interventions
Intravenous lidocaine administrationDrug
General anesthesia with intravenous lidocaine administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma lipase levelTime frame: Hour 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpital Privé des Peupliers
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.